CN111936141A - 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合 - Google Patents

包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合 Download PDF

Info

Publication number
CN111936141A
CN111936141A CN201980021573.3A CN201980021573A CN111936141A CN 111936141 A CN111936141 A CN 111936141A CN 201980021573 A CN201980021573 A CN 201980021573A CN 111936141 A CN111936141 A CN 111936141A
Authority
CN
China
Prior art keywords
cancer
trametinib
dabrafenib
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980021573.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·迈尔
王幼真
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN111936141A publication Critical patent/CN111936141A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980021573.3A 2018-03-30 2019-03-29 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合 Pending CN111936141A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650744P 2018-03-30 2018-03-30
US62/650,744 2018-03-30
PCT/IB2019/052601 WO2019186488A1 (en) 2018-03-30 2019-03-29 A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor

Publications (1)

Publication Number Publication Date
CN111936141A true CN111936141A (zh) 2020-11-13

Family

ID=66397350

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980021573.3A Pending CN111936141A (zh) 2018-03-30 2019-03-29 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合

Country Status (13)

Country Link
US (1) US20210121460A1 (enExample)
EP (1) EP3773586A1 (enExample)
JP (1) JP2021519285A (enExample)
KR (1) KR20200138303A (enExample)
CN (1) CN111936141A (enExample)
AU (1) AU2019246719B2 (enExample)
BR (1) BR112020019577A2 (enExample)
CA (1) CA3094780A1 (enExample)
CL (1) CL2020002505A1 (enExample)
IL (1) IL277380A (enExample)
MX (1) MX2020010231A (enExample)
RU (1) RU2020135055A (enExample)
WO (1) WO2019186488A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230090389A1 (en) * 2020-02-28 2023-03-23 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor
IL295626A (en) * 2020-02-28 2022-10-01 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a raf inhibitor
KR20240055721A (ko) * 2021-06-24 2024-04-29 아사나 바이오사이언시스 엘엘씨 Erk1/2 억제제 조합 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017121877A1 (en) * 2016-01-13 2017-07-20 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2ｈ-피리도[2,3-ｄ]피리미딘 유도체 및 관련 화합물
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DK3063143T3 (en) * 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017121877A1 (en) * 2016-01-13 2017-07-20 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAOHUA XUE: "An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer", 《NAT MED》, vol. 23, no. 8, 17 July 2017 (2017-07-17), pages 929 - 937 *

Also Published As

Publication number Publication date
CA3094780A1 (en) 2019-10-03
BR112020019577A2 (pt) 2021-01-05
IL277380A (en) 2020-11-30
KR20200138303A (ko) 2020-12-09
CL2020002505A1 (es) 2021-03-05
JP2021519285A (ja) 2021-08-10
EP3773586A1 (en) 2021-02-17
AU2019246719A1 (en) 2020-10-01
US20210121460A1 (en) 2021-04-29
AU2019246719B2 (en) 2022-06-16
MX2020010231A (es) 2020-10-28
WO2019186488A1 (en) 2019-10-03
RU2020135055A (ru) 2022-05-05

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
TW202313041A (zh) 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
TW202146021A (zh) 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
TW202529768A (zh) 癌症治療的療法
US20220152026A1 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
US20110086837A1 (en) Combinations of a pi3k inhibitor and a mek inhibitor
TW201924675A (zh) 包含lsz102及奧匹裡斯(alpelisib)之醫藥組合
AU2019246719B2 (en) A triple pharmaceutical combination comprising dabrafenib, trametinib and an Erk inhibitor
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
US20240238284A1 (en) Compounds and compositions for the treatment of mpnst
JP2022522873A (ja) レボケトコナゾールによる疾患の処置方法
TW202146024A (zh) 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合
CN120417928A (zh) 联合治疗肿瘤的药物
JP2019532934A (ja) 卵巣癌を治療するための方法
HK40121691A (en) Methods for treating cancer resistant to cdk4/6 inhibitors
CN117940132A (zh) Erk1/2和kras g12c抑制剂组合疗法
TW202440096A (zh) 雌激素受體降解劑之給藥方案
TR2021008987T (tr) Kanser terapi̇si̇ne yöneli̇k yöntemler

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination